Zydus Cadila Receives Us Fda Approval To Market Macitentan Tablets
Zydus Cadila Has Received Final Approval From Us Food And Drug Administration (Fda) To Market Macitentan Tablets, 10 Mg.Macitentan Is Used To Manage The Symptoms Of Pulmonary Arterial Hypertension.Macitentan Is In A Class Of Medications Called Endothelin Receptor Antagonists. It Works By Stopping The Action Of Endothelin, A Natural Substance That Causes Blood Vessels To Narrow And Prevents Normal Blood Flow In People Who Have Pulmonary Arterial Hypertension.According To The Us Fda Letter, Zydus Was One Of The First Anda Applicants To Submit A Substantially Complete Anda With A Paragraph Iv Certification For Macitentan Tablets, 10 Mg. Therefore, With This Approval, Zydus Is Eligible For 180 Days Of Shared Generic Drug Exclusivity For Macitentan Tablets, 10 Mg.The Group Now Has 314 Approvals And Has So Far Filed Over 400 Andas Since The Commencement Of The Filing Process In Fy 2003-04.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!